Joint Clinical Trials Office

You are here

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis: ECZTRA 5 (ECZema TRAlokinumab Trial No. 5) Phase 2 - Vaccine Response Trial

Clinical Trial Details

The purpose of this clinical trial is to evaluate whether treatment with the trial drug, tralokinumab, affects the immune response to vaccines in people with atopic dermatitis, also known as eczema. Subjects will receive injections of the trial medication or a placebo every other week for 14 weeks. The trial will include up to 12 office visits. There is no cost to participate in this clinical study, and reasonable travel expenses will be reimbursed. 

Key Eligibility: 
  • Open to individuals ages 18 to 54 years
  • Participants must have atopic dermatitis for at least 1 year 
  • Participants cannot be pregnant 

Contact

Elise Tetelman, PA-C, MBA
elt9059@med.cornell.edu
646-962-5565

Primary Investigator

Richard Granstein, MD

Protocol ID(s)

Weill Cornell Medicine IRB #:

1806019338A001

ClinicalTrials.gov:

NCT03562377

Status:

Open to Enrollment

Age Group

Adult

Sponsor

Drug/Device

Drug

Study Type

Phase

2